  The mechanism of SARS-CoV-2 evolution and transmission is elusive and its
understanding, a prerequisite to forecast emerging variants, is of paramount
importance. SARS-CoV-2 evolution is driven by the mechanisms at molecular and
organism scales and regulated by the transmission pathways at the population
scale. In this review, we show that infectivity-based natural selection was
discovered as the mechanism for SARS-CoV-2 evolution and transmission in July
2020. In April 2021, we proved beyond all doubt that such a natural selection
via infectivity-based transmission pathway remained the sole mechanism for
SARS-CoV-2 evolution. However, we reveal that antibody-disruptive co-mutations
[Y449S, N501Y] debuted as a new vaccine-resistant transmission pathway of viral
evolution in highly vaccinated populations a few months ago. Over one year ago,
we foresaw that mutations spike protein RBD residues, 452 and 501, would "have
high chances to mutate into significantly more infectious COVID-19 strains".
Mutations on these residues underpin prevailing SARS-CoV-2 variants Alpha,
Beta, Gamma, Delta, Epsilon, Theta, Kappa, Lambda, and Mu at present and are
expected to be vital to emerging variants. We anticipate that viral evolution
will combine RBD co-mutations at these two sites, creating future variants that
are tens of times more infectious than the original SARS-CoV-2. Additionally,
two complementary transmission pathways of viral evolution: infectivity and
vaccine-resistant, will prolong our battle with COVID-19 for years. We predict
that RBD co-mutation [A411S, L452R, T478K], [L452R, T478K, N501Y], [L452R,
T478K, E484K, N501Y], [K417N, L452R, T478K], and [P384L, K417N, E484K, N501Y]
will have high chances to grow into dominating variants due to their high
infectivity and/or strong ability to break through current vaccines, calling
for the development of new vaccines and antibody therapies.
